When a brand loses exclusivity, the challenge is not just to defend but to evolve.
As generics and biosimilars enter the market, many teams focus on what they stand to lose. The most effective LOE plans, however, are built around a different question: what can still be gained?
In The Loss of Exclusivity Planning Course for Pharma, Dr Neal Hansen and James Kettlewell discuss the PSVA Framework, developed from their years of real-world LOE experience. The framework organises late-lifecycle strategy into four interconnected areas: Product, Solution, Value, and Asset optimisation. Together, these four dimensions give teams a practical structure for identifying and acting on the opportunities that remain, even in a highly competitive, post-LOE environment.
Continue your learning from Neal and James
If you’d like to learn more from Neal and James, CELforPharma also offers a 1-day, hands-on course where you'll learn:
- What Loss of Exclusivity (LOE) means and the factors that determine both its timing and its impact
- How and why markets can behave very differently after generics or biosimilars enter across countries and within a single market
- The processes and frameworks that support effective LOE planning at global, regional, and local levels
- The toolkit of tactical options available for late-lifecycle planning, illustrated with real-world case studies
The Loss of Exclusivity Planning Course for Pharma
From Global Strategy to Local Execution
With Dr Neal Hansen & James Kettlewell
Don’t miss the latest insights from our expert faculty
Subscribe to our newsletter to:
- Stay on top of the latest expert insights
- Receive invitations to upcoming educational webinars
- Get updates on our courses and training programmes